Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

References

• Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236–301
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Edwards JEJ, Filler SG. Zygomycosis. Clinical Mycology, WE Dismukes, PG Pappas, JD Sobel. Oxford University Press, New York 2003; 241–251
   Google Scholar
• Spellberg B, Edwards J, Jr., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556–569
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851–856
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350–1360
   PubMed Web of Science ®Google Scholar
• Kwon-Chung KJ, Bennett JE. Mucormycosis. Medical Mycology. Lea & Febiger, Philadelphia 1992; 524–559
   Google Scholar
• Spellberg B. Prospects for and barriers to a fungal vaccine. Expert Opin Biol Ther 2007; 7: 1785–1788
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clinical Infectious Diseases 2008; 47: 364–371
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York, NY 1996
   Google Scholar
• Dunger DB, Sperling MA, Acerini CL, et al. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child 2004; 89: 188–194
   PubMed Web of Science ®Google Scholar
• Eledrisi MS, Alshanti MS, Shah MF, Brolosy B, Jaha N. Overview of the diagnosis and management of diabetic ketoacidosis. Am J Med Sci 2006; 331: 243–251
   PubMed Web of Science ®Google Scholar
• Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA. Long-term health-related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life. Crit Care Med 2000; 28: 3599–3605
   PubMed Web of Science ®Google Scholar
• Quartin AA, Schein RM, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 1997; 277: 1058–1063
   PubMed Web of Science ®Google Scholar
• Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347: 993–1000
   PubMed Web of Science ®Google Scholar
• Davidson TA, Caldwell ES, Curtis JR, Hudson LD, Steinberg KP. Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. JAMA 1999; 281: 354–360
   PubMedGoogle Scholar
• Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases?. Leuk Lymphoma 2004; 45: 1351–1360
   PubMed Web of Science ®Google Scholar
• Candrilli, SD MJ. How much does a hospital day cost?, In: 11th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2006. ISPOR. Philadelphia.
   Google Scholar
• 100% MEDPAR Inpatient Hospital National Data for Fiscal Year 2005 6/06 Update. Short Stay Inpatient Diagnosis Related Groups. In: Centers for Medicare and Medicaid Services, 2006. http://www.cms.hhs.gov/MedicareFeeforSvcPartsAB/Downloads/DRG05.pdf.
   Google Scholar
• Obraztsova IN, Prados N, Holzmann K, Avalos J, Cerda-Olmedo E. Genetic damage following introduction of DNA in Phycomyces. Fungal Genet Biol 2004; 41: 168–180
   Google Scholar
• Alaghehbandan R, Collins KD, Newhook LA, MacDonald D. Childhood type 1 diabetes mellitus in Newfoundland and Labrador, Canada. Diabetes Res Clin Pract 2006; 74: 82–89
   Google Scholar
• Henriksen OM, Roder ME, Prahl JB, Svendsen OL. Diabetic ketoacidosis in Denmark Incidence and mortality estimated from public health registries. Diabetes Res Clin Pract 2007; 76: 51–56
   PubMed Web of Science ®Google Scholar
• Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005; 103: 1916–1924
   PubMed Web of Science ®Google Scholar
• Loberiza FR, Jr, Serna DS, Horowitz MM, Rizzo JD. Transplant center characteristics and clinical outcomes after hematopoietic stem cell transplantation: what do we know?. Bone Marrow Transplant 2003; 31: 417–421
   PubMed Web of Science ®Google Scholar
• Fast Facts About Transplant, January 1, 2006-December 31, 2007. In:, , Scientific Registry of Transplant Recipients; 2008. US transplants.
   Google Scholar
• Ellis RW. Product development plan for new vaccine technologies. Vaccine 2001; 19: 1559–1566
   PubMed Web of Science ®Google Scholar
• Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: results of population-based laboratory active surveillance. Clinical Infectious Diseases 1998; 27: 1138–1147
   PubMed Web of Science ®Google Scholar
• Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplantation 1999; 24: 307–312
   PubMed Web of Science ®Google Scholar
• Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17: 517–525
   PubMed Web of Science ®Google Scholar
• Angus DC, Musthafa AA, Clermont G, et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163: 1389–1394
   PubMed Web of Science ®Google Scholar
• Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci 2004; 7: 43–49
   PubMedGoogle Scholar
• Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis 2008; 46: 1–13
   PubMed Web of Science ®Google Scholar
• Nordoy T, Aaberge IS, Husebekk A, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002; 19: 71–78
   PubMed Web of Science ®Google Scholar
• Leung TF, Li CK, Hung EC, et al. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers. Eur J Haematol 2004; 72: 353–357
   PubMed Web of Science ®Google Scholar
• Somjee S, Pai S, Parikh P, et al. Passive active prophylaxis against Hepatitis B in children with acute lymphoblastic leukemia. Leuk Res 2002; 26: 989–992
   Google Scholar
• Feldman S, Gigliotti F, Shenep JL, Roberson PK, Lott L. Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J Infect Dis 1990; 161: 926–931
   PubMed Web of Science ®Google Scholar
• Sinsalo M, Aittoniemi J, Kayhty H, Vilpo J. Haemophilus influenzae type b (Hib) antibody concentrations and vaccination responses in patients with chronic lymphocytic leukaemia: predicting factors for response. Leuk Lymphoma 2002; 43: 1967–1969
   PubMed Web of Science ®Google Scholar
• King JC, Jr, Vink PE, Farley JJ, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15: 192–196
   PubMed Web of Science ®Google Scholar
• Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi). Vaccine 1999; 17: 2941–2945
   PubMed Web of Science ®Google Scholar
• dos Santos Sde S, Lopes MH, Simonsen V, Caiaffa Filho HH. Haemophilus influenzae type b immunization in adults infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 2004; 20: 493–496
   Google Scholar
• Rutstein RM, Rudy BJ, Cnaan A. Response of human immunodeficiency virus-exposed and -infected infants to Haemophilus influenzae type b conjugate vaccine. Arch Pediatr Adolesc Med 1996; 150: 838–841
   PubMedGoogle Scholar
• Chokephaibulkit K, Phongsamart W, Vanprapar N, Chotpitayasunondh T, Chearskul S. Catch-up vaccination against Haemophilus influenzae type b in human immunodeficiency virus-infected Thai children older than 2 years old. Vaccine 2004; 22: 2018–2022
   PubMed Web of Science ®Google Scholar
• Dockrell DH, Poland GA, Steckelberg JM, et al. Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response. Vaccine 1999; 17: 2779–2785
   PubMed Web of Science ®Google Scholar
• Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr 2001; 139: 305–310
   PubMed Web of Science ®Google Scholar
• Tedaldi EM, Baker RK, Moorman AC, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004; 38: 1478–1484
   PubMed Web of Science ®Google Scholar
• Kemper CA, Haubrich R, Frank I, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003; 187: 1327–1331
   PubMed Web of Science ®Google Scholar
• Madhi SA, Petersen K, Khoosal M, et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002; 21: 315–321
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341–1348
   PubMed Web of Science ®Google Scholar
• Guerrero M, Kruger S, Saitoh A, et al. Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention. Aids 1999; 13: 1971–1975
   PubMed Web of Science ®Google Scholar
• Greenwood B. Interpreting vaccine efficacy. Clin Infect Dis 2005; 40: 1519–1520
   Google Scholar
• Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005; 40: 1511–1518
   PubMed Web of Science ®Google Scholar